Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07084844 · ClinicalTrials.gov registry record
Patient Reported Outcomes With WaveLight Plus LASIK
A clinical trial of Myopia and Astigmatism, sponsored by Mann Eye Institute.
- Recruiting
- Registry status
- 52
- Enrollment target
- 1
- Study location
NCT07084844: Recruiting study of Myopia and Astigmatism, sponsored by Mann Eye Institute.
NCT07084844 is a study of Myopia and Astigmatism that is actively recruiting participants, run by Mann Eye Institute. The registered enrollment target is 52 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07084844, a study of Myopia and Astigmatism, is actively recruiting participants, sponsored by Mann Eye Institute.
- RECRUITING
- Registry status
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a single-site, single-arm, prospective, observational study of subject satisfaction, quality of vision, and quality of life after bilateral LASIK surgery. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the adapted PROWL and the Quality-of-Life Impact of Refractive Correction (QIRC) Questionnaire.
Conditions Studied
Interventions
- DEVICE WaveLigh Plus LASIK
Study Locations (1)
Texas
- Mann Eye Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2025-09-05 |
| Est. Completion | 2026-09-01 |
What NCT07084844 shows while recruiting
NCT07084844 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Myopia appearing as the primary indexed condition, and to 1 intervention - of which WaveLigh Plus LASIK is the first listed.
NCT07084844 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07084844 about?
NCT07084844 is a clinical study titled "Patient Reported Outcomes With WaveLight Plus LASIK". This study is a single-site, single-arm, prospective, observational study of subject satisfaction, quality of vision, and quality of life after bilateral LASIK surgery. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, an...
What is the current status of trial NCT07084844?
This trial is currently recruiting. The enrollment target is 52 participants. The study started on 2025-09-05. Estimated completion is 2026-09-01.
What conditions does trial NCT07084844 study?
This clinical trial studies the following conditions: Myopia, Astigmatism.
What interventions are being tested in trial NCT07084844?
The interventions under investigation include: WaveLigh Plus LASIK (DEVICE).
Who is sponsoring clinical trial NCT07084844?
This trial is sponsored by Mann Eye Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07084844 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07084844's enrollment target sits among peer trials
52 65th of 90 higher than 25 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Clinical Evaluation of WaveLight Plus LASIK
RECRUITING
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI